In last trading session, Esperion Therapeutics Inc (NASDAQ:ESPR) saw 6.95 million shares changing hands with its beta currently measuring 0.65. Company’s recent per share price level of $0.73 trading at -$0.05 or -6.49% at ring of the bell on the day assigns it a market valuation of $144.68M. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 7.05 million shares which gives us an average trading volume of 5.03 million if we extend that period to 3-months.
For Esperion Therapeutics Inc (ESPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.88. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Upright in the red during last session for losing -6.49%, in the last five days ESPR remained trading in the red while hitting it’s week-highest on Friday, 05/09/25 when the stock touched $0.73 price level, adding 21.59% to its value on the day. Esperion Therapeutics Inc’s shares saw a change of -66.82% in year-to-date performance and have moved -16.18% in past 5-day. Esperion Therapeutics Inc (NASDAQ:ESPR) showed a performance of -26.93% in past 30-days. Number of shares sold short was 29.86 million shares which calculate 5.19 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 90.88% to its current value. Analysts have been projecting 8 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -995.89% in reaching the projected high whereas dropping to the targeted low would mean a loss of -995.89% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 40.11% during past 5 years.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
Insiders are in possession of 0.51% of company’s total shares while institution are holding 57.64 percent of that, with stock having share float percentage of 57.93%. Investors also watch the number of corporate investors in a company very closely, which is 57.64% institutions for Esperion Therapeutics Inc that are currently holding shares of the company. WASATCH ADVISORS LP is the top institutional holder at ESPR for having 16.86 million shares of worth $37.44 million. And as of 2024-06-30, it was holding 8.9319 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 13.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4068 of outstanding shares, having a total worth of $31.04 million.
On the other hand, WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 6.68 shares of worth $4.87 million or 3.37% of the total outstanding shares. The later fund manager was in possession of 6.18 shares on Dec 31, 2024 , making its stake of worth around $4.51 million in the company or a holder of 3.12% of company’s stock.
